Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · August 15, 2022

Markers of Severe CRS and ICANS in Patients With B-Cell ALL Receiving CAR T-Cell Therapy

Clinical Cancer Research

 

Additional Info

Clinical Cancer Research
Comprehensive Serum Proteome Profiling of Cytokine Release Syndrome and Immune Effector Cell Associated Neurotoxicity Syndrome in B-Cell ALL Patients Receiving CART19
Clin. Cancer Res 2022 Jun 15;[EPub Ahead of Print], C Diorio, R Shraim, R Myers, EM Behrens, S Canna, H Bassiri, R Aplenc, C Burudpakdee, F Chen, AM DiNofia, S Gill, V Gonzalez, MP Lambert, A Barz Leahy, BL Levine, RB Lindell, SL Maude, JJ Melenhorst, H Newman, J Perazzelli, AE Seif, SF Lacey, CH June, DM Barrett, SA Grupp, DT Teachey

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading